Skip to main content

Table 2 Common adverse events

From: The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial

Most frequently observed AE resulting from study drug

Most frequently observed laboratory abnormalities

Mouth ulcers

Neutropenia

Rash

Thrombocytopenia

Infections

Hypercholesterolemia

Diarrhoea

Hypertriglyceridemia

Fatigue

Hypophosphatemia

Headache

 

Anorexia

 

Nausea

 

Vomiting

 

Non-infectious pneumonitis

 
  1. AE adverse events
Back to article page

Trials

ISSN: 1745-6215